MiRXES
Convergence in the blood: How AI and biotech are rewriting cancer detection across Asia
Industrial bases, not just science, will determine whether breakthroughs become real benefits.
Singapore’s Mirxes to list in Hong Kong after securing $50M in Series D funding
Mirxes Holding Company Limited, a Singapore-headquartered biotech firm, announced Tuesday that it has filed listing application with The Stock Exchange of Hong Kong Limited after securing $50 million Series D funding.
MiRXES secures $77M Series C funding to accelerate multi-cancer early detection pipeline
Led by CR-CP Life Science Fund, this new capital will support MiRXES’s growth as a global leader in cancer early detection tests and preventive healthcare.
